| Symbol
| SLC22A3
| contributors: mct/npt - updated : 07-10-2015
|
| HGNC name
| solute carrier family 22 (extraneuronal monoamine transporter), member 3
|
| HGNC id
| 10967
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
| --low
|
| |
lower expression of mRNAs in pre-eclamptic placentae as compared to the control group (Bottalico 2004) | | tumoral
|
|
| --low
|
|
inversely correlated with Prostate carcinoma progression, with reduced expression as disease advances  | | constitutional
|
|
| --over
|
| |
of SLC22A3 and SLC47A1 in human placenta indicates these transporters may play a role in fetal protection preferentially at earlier stages of gestation | |
| Susceptibility
|
to coronary artery disease to the development of polysubstance use in Japanese patients with Methamphetamine (MAP) dependence to euphoria and potential for addiction and susceptibility to the toxicity of substances of abuse |
| Variant & Polymorphism
SNP
| four SNPs overlapping the SLC22A3-LPAL2-LPA gene cluster associated to risk of coronary artery disease (Tregouet 2009) |
|
polymorphisms of SLC22A3 related to the development of polysubstance use in Japanese patients with MAP dependence (Aoyama 2006) |
|
polymorphisms may reduce or inactivate the function of SLC22A3 and therefore enhance the euphoria and potential for addiction and susceptibility to the toxicity of substances of abuse (Cui 2009) |
| 
|
Candidate gene
Marker
| Therapy target
| Monoamine transporters may serve as a protective mechanism preventing vasoconstriction in the placental vascular bed and thereby securing a stable blood flow to the fetus (Bottalico 2004) | |
| | |